CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Hairy Cell Leukemia
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Mucosa-Associated Lymphoid Tissue Lymphoma
- Refractory Follicular Lymphoma
- Refractory Hairy Cell Leukemia
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Small Lymphocytic Lymphoma
Interventions
- DRUG: Lenalidomide
- BIOLOGICAL: Obinutuzumab
- DRUG: Oral Azacitidine
Sponsor
Joseph Tuscano
Collaborators
- [object Object]
- [object Object]